# Utility of PharmacoGenomics for Reducing Adverse Drug Effects

> **NCT02081872** · — · UNKNOWN · sponsor: **Companion Dx Reference Lab, LLC** · enrollment: 279000 (estimated)

## Conditions studied

- Genetics of Drug Metabolism

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT02081872
- **Lead sponsor:** Companion Dx Reference Lab, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-04
- **Primary completion:** 2017-07
- **Final completion:** 2017-07
- **Target enrollment:** 279000 (ESTIMATED)
- **Last updated:** 2015-10-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02081872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02081872, "Utility of PharmacoGenomics for Reducing Adverse Drug Effects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02081872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*